Sanofi’s Dupixent (dupilumab) Receives European Commission Approval for Severe Asthma with Type 2 Inflammation

 Sanofi’s Dupixent (dupilumab) Receives European Commission Approval for Severe Asthma with Type 2 Inflammation

Sanofi’s Dupixent (dupilumab) Receives European Commission Approval for Severe Asthma with Type 2 Inflammation

Shots:

  • The approval is based on LIBERTY ASTHMA program including two P-III (QUEST and VENTURE) & one P-IIb studies assessing Dupixent + SOC vs PBO in 2,888 adults and adolescents aged 12+ in patients with severe asthma + type 2 inflammation, characterized by raised blood eosinophils and/or fractional exhaled nitric oxide
  • Results in patients with eosinophils ≥300 cells/µliter & FeNO levels ≥25 parts/billion: reduction in severe exacerbations (67% & 65%); Improvement in lung function, @12wks. improvement in FEV1 (33% vs 16% & 30% vs 14%) (26% vs 10%), reduction in oral corticoid use @24wks. (70% vs 42%)
  • Dupixent (dupilumab,200mg & 300mg) is a biologic, targeting IL-4 & IL-13, marketed as a pre-filled syringe and has received EU’s & FDA approval for moderate-to-severe atopic dermatitis & asthma respectively

Click here to read full press release/ article | Ref: Sanofi | Image: The Economic Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post